Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Instil Bio ( (TIL) ) has issued an announcement.
Instil Bio reported its fourth quarter and full year 2024 financial results, highlighting a decrease in cash and marketable securities compared to the previous year. The company anticipates significant clinical developments in 2025, including data updates and trial initiations for its lead asset AXN-2510/IMM2510 in collaboration with ImmuneOnco, which could impact its operations and industry positioning.
More about Instil Bio
Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Its subsidiaries include Axion Bio, Inc., whose lead asset AXN-2510/IMM2510 is a novel bispecific antibody in development for treating multiple solid tumor cancers.
YTD Price Performance: -7.03%
Average Trading Volume: 94,560
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $131.2M
Find detailed analytics on TIL stock on TipRanks’ Stock Analysis page.